Enlivex Therapeutics Ltd. (TLV:ENLV)
Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
521.90
+36.90 (7.61%)
Jul 31, 2025, 5:24 PM IDT

Enlivex Therapeutics Company Description

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.

Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis.

The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial.

Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.

Enlivex Therapeutics Ltd.
Enlivex Therapeutics logo
CountryIsrael
Founded2005
IndustryBiotechnology
SectorHealthcare
CEOOren Hershkovitz

Contact Details

Address:
14 Einstein Street
Ness Ziona, 7403618
Israel
Phone972 2 620 8072
Websiteenlivex.com

Stock Details

Ticker SymbolENLV
ExchangeTel Aviv Stock Exchange
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberIL0011319527
SIC Code2836

Key Executives

NamePosition
Dr. Oren Hershkovitz Ph.D.Chief Executive Officer
Shai Novik M.B.A.Executive Chairman
Prof. Dror Mevorach M.D.Founder and Scientific Advisor
Shachar Shlosberger CPAChief Financial Officer
Dr. Veronique Amor-BaroukhSenior Director of Operations
Sigal AradDirector of Human Resources
Dr. Einat Galamidi M.D.Chief Medical Officer